Boston Scientific announced a cash‑and‑stock agreement to acquire Penumbra for about $14.5 billion, moving to expand its footprint in thrombectomy, embolization and other interventional vascular segments. The acquisition targets Penumbra’s clot‑removal and embolization franchises and is positioned as a strategic extension into fast‑growing vascular markets. Company statements highlighted revenue synergies and market access benefits; analysts noted the deal follows elevated M&A activity in med‑tech post‑JPM and reflects continued strategic consolidation in interventional devices. The transaction is subject to customary approvals and is expected to close in 2026.